Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

References

• MeltzerHYUpdate on typical and atypical antipsychotic drugsAnnu Rev Med20136439340623020880
   PubMed Web of Science ®Google Scholar
• HaroJMSalvador-CarullaLThe SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophreniaCNS Drugs200620429330116599647
   PubMed Web of Science ®Google Scholar
• NewcomerJWMetabolic considerations in the use of antipsychotic medications: a review of recent evidenceJ Clin Psychiatry200768Suppl 1202717286524
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• MeyerJMKoroCEThe effects of antipsychotic therapy on serum lipids: a comprehensive reviewSchizophr Res200470111715246458
   PubMed Web of Science ®Google Scholar
• MeyerJMCardiovascular illness and hyperlipidemia in patients with schizophreniaMeyerJMNasrallahHAMedical Illness and SchizophreniaWashington, DCAmerican Psychiatric Publishing20035083
   Google Scholar
• Le FevrePDImproving the physical health of patients with schizophrenia: therapeutic nihilism or realism?Scott Med J2001461111311310354
   PubMed Web of Science ®Google Scholar
• JenkinsDJKendallCWMarchieAEffects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive proteinJAMA2003290450251012876093
   PubMed Web of Science ®Google Scholar
• Primo-ParmoSLSorensonRCTeiberJLa DuBNThe human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene familyGenomics19963334985078661009
   PubMed Web of Science ®Google Scholar
• GanKNSmolenAEckersonHWLa DuBNPurification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activitiesDrug Metab Dispos19911911001061673382
   PubMed Web of Science ®Google Scholar
• OsakiFIkedaYSuehiroTRoles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cellsAtherosclerosis2004176227928715380450
   PubMed Web of Science ®Google Scholar
• BrophyVHJampsaRLClendenningJBMcKinstryLAJarvikGPFurlongCEEffects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expressionAm J Hum Genet20016861428143611335891
   PubMed Web of Science ®Google Scholar
• SchraderCRimbachGDeterminants of paraoxonase 1 status: genes, drugs and nutritionCurr Med Chem201118365624564322172068
   PubMed Web of Science ®Google Scholar
• LitvinovDMahiniHGarelnabiMAntioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseasesN Am J Med Sci201241152353223181222
   PubMedGoogle Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashington, DCAmerican Psychiatric Publishing2000
   Google Scholar
• CorapciogluAAydemirOYildizMDSM-IV Structured Clinical Interview for DSM-IV (SCID-IV), Turkish Version (Turkish)Ankara, TurkeyHekimler Yayin Birligi1999
   Google Scholar
• FirstMBSpitzerRLGibbonMWilliamsJBWStructured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV)Washington, DCAmerican Psychiatric Publishing1996
   Google Scholar
• CampsJMarsillachJJovenJThe paraoxonases: role in human diseases and methodological difficulties in measurementCrit Rev Clin Lab Sci20094628310619255916
   PubMed Web of Science ®Google Scholar
• IsikAKocaSSUstundagBCelikHYildirimAParaoxonase and arylesterase levels in rheumatoid arthritisClin Rheumatol200726334234816642406
   PubMed Web of Science ®Google Scholar
• ErelOA novel automated method to measure total antioxidant response against potent free radical reactionsClin Biochem20043711211914725941
   PubMed Web of Science ®Google Scholar
• ErelOA new automated colorimetric method for measuring total oxidant statusClin Biochem200538121103111116214125
   PubMed Web of Science ®Google Scholar
• DavidsonMCan premorbid and prodromal markers associated with psychosis be utilized for early detection and secondary prevention of schizophrenia?Dialogues Clin Neurosci20013213814322033778
   PubMedGoogle Scholar
• OsbyUCorreiaNBrandtLEkbomASparénPMortality and causes of death in schizophrenia in Stockholm county, SwedenSchizophr Res2000451–2212810978869
   PubMed Web of Science ®Google Scholar
• BouchardRHDemersMFSimoneauIAtypical antipsychotics and cardiovascular risk in schizophrenic patientsJ Clin Psychopharmacol200121111011111199934
   PubMed Web of Science ®Google Scholar
• AtmacaMKulogluMTezcanGeciciOUstundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidolSchizophr Res20036019910012505146
   PubMed Web of Science ®Google Scholar
• AtmacaMKulogluMTezcanEUstundagBSerum leptin and triglyceride levels in patients on treatment with atypical antipsychoticsJ Clin Psychiatry200364559860412755665
   PubMed Web of Science ®Google Scholar
• WirshingDABoydJAMengLRBallonJSMarderSRWirshingWCThe effects of novel antipsychotics on glucose and lipid levelsJ Clin Psychiatry2002631085686512416594
   PubMed Web of Science ®Google Scholar
• MeyerJMA retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 yearJ Clin Psychiatry200263542543312019668
   PubMed Web of Science ®Google Scholar
• KoroCEFedderDOL’ItalienGJAn assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patientsArch Gen Psychiatry200259111021102612418935
   PubMed Web of Science ®Google Scholar
• NasrallahHAPerryCLLoveENasrallahATAre there ethnic differences in hypertriglyceridemia secondary to olanzapine treatmentPoster presented at 40th Annual Meeting of the American College of NeuropsychopharmacologyDecember 10, 2001Waikoloa, Hawaii
   Google Scholar
• MeyerJMEffects of atypical antipsychotics on weight and serum lipid levelsJ Clin Psychiatry200162Suppl 27273411806486
   PubMed Web of Science ®Google Scholar
• SheitmanBBBirdPMBinzWAkinliLSanchezCOlanzapine-induced elevation of plasma triglyceride levelsAm J Psychiatry199915691471147210484969
   PubMed Web of Science ®Google Scholar
• OsserDNNajarianDMDufresneRLOlanzapine increases weight and serum triglyceride levelsJ Clin Psychiatry1999601176777010584766
   PubMed Web of Science ®Google Scholar
• KryzhanovskayaLAXuWMillenBAAcharyaNJenKYOsuntokunOComparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapineJ Child Adolesc Psychopharmacol201222215716522372514
   PubMed Web of Science ®Google Scholar
• KaushalJBhutaniGGuptaRComparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidoneSingapore Med J201253748849222815019
   PubMed Web of Science ®Google Scholar
• ShaoPOuJWuR[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia]Zhong Nan Da Xue Xue Bao Yi Xue Ban2013384365369 Chinese23645236
   PubMedGoogle Scholar
• GoodnickPJJerryJMAripiprazole: profile on efficacy and safetyExpert Opin Pharmacother20023121773178112472374
   PubMedGoogle Scholar
• LeeEChowLYLeungCMMetabolic profile of first and second generation antipsychotics among Chinese patientsPsychiatry Res2011185345645820554016
   PubMed Web of Science ®Google Scholar
• MorenoCMerchán-NaranjoJAlvarezMMetabolic effects of second generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnosesBipolar Disord201012217218420402710
   PubMed Web of Science ®Google Scholar
• HuSYaoMPetersonBSA randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patientsPsychopharmacology (Berl) Epub452013
   Web of Science ®Google Scholar
• BoboWVEpsteinRASheltonRCOlanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trialHum Psychopharmacol2010251303620029794
   PubMed Web of Science ®Google Scholar
• NewcomerJWMeyerJMBakerRAChanges in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapineSchizophr Res20081062–330030718973991
   PubMed Web of Science ®Google Scholar
• WetterlingTBodyweight gain with atypical antipsychotics. A comparative reviewDrug Saf2001241597311219487
   PubMed Web of Science ®Google Scholar
• DomonSECargileCSQuetiapine-associated hyperglycemia and hypertriglyceridemiaJ Am Acad Child Adolesc Psychiatry200241549549612014779
   PubMed Web of Science ®Google Scholar
• MeyerJMNovel antipsychotics and severe hyperlipidemiaJ Clin Psychopharmacol200121436937411476120
   PubMed Web of Science ®Google Scholar
• ShawJALewisJEPascalSA study of quetiapine: efficacy and tolerability in psychotic adolescentsJ Child Adolesc Psychopharmacol200111441542411838824
   PubMed Web of Science ®Google Scholar
• ShirzadiAAGhaemiSNSide effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndromeHarv Rev Psychiatry200614315216416787887
   PubMed Web of Science ®Google Scholar
• ManfrediRChiodoFDisorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and and role of hypolipidaemic therapy with bezafibrateJ Infect200142318118811545549
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• GungorOKircelliFDemirciMSSerum paraoxonase 1 activity predicts arterial stiffness in renal transplant recipientsJ Atheroscler Thromb2011181090190521737961
   PubMed Web of Science ®Google Scholar
• WangYFuWXieFCommon polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han populationJ Hum Genet201055849049420485444
   PubMed Web of Science ®Google Scholar
• WangMLangXCuiSQuantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease riskDNA Cell Biol201231697598222320866
   PubMed Web of Science ®Google Scholar
• ZhaoYMaYFangYAssociation between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studiesMol Genet Metab2012105114114822030099
   PubMed Web of Science ®Google Scholar